



## COVID-END partners coordination call

Agenda for 15 April 2021

<https://zoom.us/j/6163788736>

|   |               |
|---|---------------|
| <b>1. INTRODUCTIONS</b>   | <b>3 min</b>  |
| <b>2. REVIEW OF COVID-END ACTION ITEMS</b><br><br>a. Review partner notes from 1 April (see attachment 2)   | <b>2 min</b>  |
| <b>3. COVID-END NETWORK UPDATES</b><br><br>a. Global commission<br>b. Identify current methodological issues related to the COVID-19 evidence response <ol style="list-style-type: none"> <li>i. What constitutes a living evidence synthesis (or what parameters of living evidence syntheses that should be explicitly documented)?</li> <li>ii. How to approach the quick and clean enough appraisal of guidelines?</li> <li>iii. Whether to include ‘old’ studies about COVID-19 in evidence syntheses? (e.g., because of the emergence of variants and vaccines, with the latter being important context to survey data about vaccine confidence and uptake)?</li> <li>iv. How to engage citizen partners in rapid syntheses? (note that Maureen Smith has shared an annotated list of resources with the secretariat for addition to the website)</li> <li>v. How to fill the gap left between what existing evidence syntheses are addressing and what decision-makers are asking?</li> </ol> c. COVID-END anniversary <ol style="list-style-type: none"> <li>i. Tentatively planning a webinar to reflect on lessons learned over the 12-15 months into COVID-END response</li> </ol> | <b>15 min</b> |
| <b>4. PARTNER PROFILE</b><br><br>a. Highlighting partners’ projects and efforts towards the COVID-19 response <ol style="list-style-type: none"> <li>i. McMaster PLUS</li> <li>ii. Evidence Synthesis Ireland</li> </ol>  | <b>30 min</b> |
| <b>5. NEWS AND INITIATIVES OF INTEREST TO PARTNERS</b><br><br>a. Evidence Synthesis Ireland’s <a href="#">Priority III study</a> <ol style="list-style-type: none"> <li>i. Online survey asking patient and public representatives, reviewers, researchers, clinicians and policymakers to select the 10 questions that are most important for future research to address</li> <li>ii. Survey can be found <a href="#">here</a></li> </ol> b. ACTS COVID-19 Evidence to Guidance to Action Collaborative developing Living Evidence Guidance dashboards   | <b>5 min</b>  |

|  |              |
|--|--------------|
| <ul style="list-style-type: none"><li>i. Dashboards leverage the <a href="#">COVID-END inventory of best evidence syntheses</a> and offerings from several COVID-END partners</li><li>ii. Input from COVID-END partners is welcomed to make the dashboards more helpful to users and to leverage pertinent evidence and guidance resources</li><li>iii. See <a href="#">here</a> for further details</li></ul> |              |
| <b>6. ANY OTHER BUSINESS</b>   | <b>5 min</b> |